CBB, probably some new business development under the new regime which would give analysts some impetus to revisit Amarin's new dawning. Certainly, AD has the contacts to say "hey come look at our new company" it's great that he is laser focused on the biotech space and his reputation is well known thanks to his success with the Medicine Company.
News 
Market Data 
Discover 
